Although Pafolacianine is targeted to FRα, it may also bind to folate receptor beta (FRβ), another isoform of the folate receptor. This hinders IMI of LNs with cancer cells because macrophages express FRβ, and this expression is particularly prominent in tumor-associated macrophages (TAMs). This evidence concerns the gene FOLR2 and neoplasm.